Research progress in role of SGLT2i in atherosclerotic cardiovascular disease with diabetes mellitus
  
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2021.04.062
Key words:cardiovascular diseases  SGLT2 inhibitor  diabetes mellitus  atherosclerosis This work was supported by National Natural Science Foundation of China
Author NameAffiliationE-mail
WANG Ji-Hang Chinese PLA Medical College, Beijing 100853, China
Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
Department of Cardiovascular Disease, Hainan Hospital, Chinese PLA General Hospital, Sanya 572013, Hainan Province, China 
fuzhenh@126.comresearch 
SHEN Ming-Zhi Department of Cardiovascular Disease, Hainan Hospital, Chinese PLA General Hospital, Sanya 572013, Hainan Province, China fuzhenh@126.comresearch 
JIAO Yang Chinese PLA Medical College, Beijing 100853, China
Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China 
fuzhenh@126.comresearch 
FU Zhen-Hong Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
National Center for Clinical Medicine of Geriatric Diseases, Beijing 100853, China 
fuzhenh@126.comresearch 
Hits: 502
Download times: 468
Abstract:
      Diabetes is a global epidemic, and poor blood glucose control has been one of the primary causes of death for patients with cardiovascular diseases. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel hypoglycemic agent, has attracted extensive attention due to their prominent protective action on cardiovascular system in addition to the hypoglycemic effect demonstrated in experimental and clinical studies. Previous large randomized controlled trials for SGLT2i (EMPA-RED, CANVAS, DELCARE TIMI-58) confirmed that SGLT2i, either as primary prevention or as secondary prevention, could significantly reduce the risk of cardiovascular deaths, non-fatal myocardial infarction and non-fatal stroke in patients with coronary artery disease and diabetes mellitus. However, there have been limited findings on the actions of SGLT2i, particularly their direct effects, in atherosclerotic cardiovascular disease (ASCVD). This review summarizes the research progress in the role of SGLT2i in ASCVD with diabetes, in an effort to provide more evidence for the clinical treatment of these patients.
Close